Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: raltegravir + [doc] + 0.36  Related to the article below (Last Update: 8/5/2008)

Guidelines Suggest Earlier Treatment for HIV-Infected Patients ...
DG News -
... adding that treatment options have been enhanced with the approval of the integrase strand inhibitor raltegravir, the CCR5-antagonist maraviroc, ...
New HIV Treatment Guidelines Issued Medscape (subscription)
all 2 news articles »

Oneindia
New HIV Drug Offers Hope For
Oneindia, India - Aug 4, 2008
They say that clinical trials have shown that raltegravir - already available in Australia - is safe and effective and has minimal side-effects when used ...
New HIV inhibitor
Science News - Jul 23, 2008
By Rachel Ehrenberg HINDERING HIVThis illustration shows the chemical makeup of the new HIV drug raltegravir. The molecule acts as an integrase inhibitor ...
Potent new HIV drug is trialled The Canberra Times
HIV Integrase Inhibitors ? Out of the Pipeline and into the Clinic New England Journal of Medicine (subscription)
New hope for HIV sufferers The Age
Newswise (press release) - Trading Markets (press release)
all 26 news articles »  MRK - OTC:CMTX
Drug Holds Promise Against AIDS
Washington Post, United States - Jul 24, 2008
The drug, known as raltegravir (Isentress), almost doubles the likelihood that patients will beat back the AIDS virus despite being immune to other ...
Doctors raise hope for new HIV drug Houston Chronicle
In Additional Subgroup Analysis, ISENTRESS Helped to Increase CD4 ... WebWire (press release)
Study Disproves Belief That Hepatitis C Blunts HIV Drugs U.S. News & World Report
all 21 news articles »
Merck?s Raltegravir HIV drug shows considerable promise in ...
MedIndia, India - Jul 26, 2008
The drug raltegravir is already available in Australia and is listed on the Pharmaceutical Benefits Scheme. Clinical trials show that it is safe, ...
Raltegravir drug combo works against highly resistant strain of HIV
News-Medical.net, Australia - Jul 24, 2008
The new drug, raltegravir, offers hope to millions afflicted with this particular strain of the virus. The study which was led by Dr. Roy T. Steigbigel, ...
Combination therapy for HIV Australian Life Scientist
all 2 news articles »
Raltegravir (Isentress) Effective Against Drug-Resistant HIV
MedPage Today, NJ - Jul 23, 2008
By Michael Smith, North American Correspondent, MedPage Today STONY BROOK, NY, July 23 -- The integrase inhibitor raltegravir (Isentress), the first in its ...
New England Journal of Medicine Reports raltegravir Suppressed HIV ...
PharmiWeb.com (press release), UK - Jul 24, 2008
The reduction in viral load and increases in CD4 cells that we???ve seen with raltegravir in combination with other anti-HIV medicines compared to placebo, ...
Gilead Initiates Phase III Clinical Trial of Elvitegravir, an ...
MarketWatch - Jul 22, 2008
Trial participants will receive either once-daily elvitegravir 150 mg or twice-daily raltegravir 400 mg. Patients' background regimens will be based on the ...
Gilead Sciences starts clinical trial of another HIV drug Bizjournals.com
all 23 news articles »  GILD
AHF Praises Merck for AIDS Drug Price Freeze in US
MarketWatch -
... AIDS drug therapy Isentress (raltegravir) for US government programs such as the federally funded, state-run AIDS Drug Assistance Programs (ADAP). ...
Merck Responds to Aids Activists' Pleas; Reduces Price of Stocrin ... MarketWatch
all 51 news articles »  MRK
Source: Google News

[DOC] HIV/AIDS NEWS
YQ Answered - bcpwa.org
... d. Raltegravir Shows Sustained Effect In Highly Treatment-Experienced Patients. ... d.
Raltegravir Shows Sustained Effect In Highly Treatment-Experienced Patients. ...
-

[DOC] HIV/AIDS NEWS
AMH Honoured - bcpwa.org
... Also: Merck's Antiretroviral Raltegravir Found To Reduce Viral Loads Among
HIV-Positive People With Drug Resistance, Study Says. Apr 17, 2007. ...

[DOC] CDHS MEDI-CAL FRAUD HOTLINE
C Drugs, B Unit, DTP Additions - files.medi-cal.ca.gov
... Therapeutic Classifications. Addition, effective October 18, 2007. Drug. Strength
and/or Size, Billing Unit. * RALTEGRAVIR, * Restricted to ...

A refined pharmacophore model for HIV-1 integrase inhibitors: Optimization of potency in the 1H- …
L De Luca, ML Barreca, S Ferro, N Iraci, M … - Bioorganic & Medicinal Chemistry Letters, 2008 - Elsevier
... controls. 7 More recently, the FDA approved MK-0518 (raltegravir) as the
first drug (Isentress) that is active against IN enzyme. 8. ...

Update on Antiretroviral Toxicities (Slides With Transcript) CME
CME Medscape, M Connect, C Care, G Surgery, M … - medscape.com
... So a patient sits in your office now and says, "Well doc, like how long do I ...
You're going to hear a little bit more about raltegravir later, but to focus on ...

[DOC] Medical Services? Obstetrics December 2007? Bulletin 402
I Codes, IV Update, FA as Benefit, FR Adjusted - filessysdev.medi-cal.ca.gov
... 4 ? Therapeutic Classifications. Addition, effective October 18, 2007. Drug.
Strength and/or Size. * RALTEGRAVIR, * Restricted to use ...

[CITATION] Medical Services? General Medicine December 2007? Bulletin 402
I Codes, IV Update
-

[DOC] Recherche clinique
C sant? Inserm, C Gu?laud - refer.sn
... http://www.orpha.net/actor/Orphanews/2007/doc/increm.pdf. ... Administration unanimously
recommended approval of ISENTRESS? (raltegravir), Merck's investigational ...

[DOC] HIV/AIDS NEWS -
LL Camp - bcpwa.baremetal.com
HIV/AIDS NEWS, May 31, 2007. HIV/AIDS News is published by the British Columbia
Persons With AIDS Society. This publication is a compilation ...

[PDF] Antiviral Drugs IN THE Treatment OF AIDS -
HJ Stellbrink - Eur J Med Res, 2007 - maraviroc.de
... ad- vanced compounds likely to become licensed soon in- clude the NNRTIs rilpivirine
and etravirine, the inte- grase inhibitors raltegravir and elvitegravir ...

Source: Google Scholar

FDA Panel To Review Merck's Antiretroviral Raltegravir In September

An FDA panel of experts will review Merck's experimental antiretroviral drug raltegravir in September, the agency announced on Wednesday, the AP/Yahoo! Finance News reports (AP/ Yahoo! Finance News, 7/11).

Merck in June announced that FDA granted priority review status to raltegravir, an experimental integrase inhibitor.

Raltegravir effectively decreases HIV viral loads after 24 weeks of use among HIV-positive people who have not responded to other treatments, according to a study published in the April 14 online edition of the journal Lancet.

Raltegravir works by blocking an HIV enzyme called integrase. Integrase is one of the three enzymes necessary for HIV to replicate in the body, and integrase inhibitors stop HIV from inserting its genes into uninfected DNA.

The other two enzymes necessary for viral replication, reverse transcriptase and protease, already are targeted by a variety of antiretroviral drugs.

Merck said that if the drug is approved, it will be used in combination with standard oral antiretrovirals by HIV-positive people who have developed resistance to their current treatments.

The company said it will begin filing marketing applications outside the U.S. Raltegravir will be sold under the brand name Isentress (Kaiser Daily HIV/AIDS Report, 6/29).

According to documents posted to FDA's Web site, the panel plans to assess the safety and efficacy of raltegravir on Sept. 5 (AP/Yahoo! Finance News, 7/11).

"Reprinted with permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy.

The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.